Hologic, Inc. (NASDAQ:HOLX) Receives $79.31 Average Price Target from Analysts

Shares of Hologic, Inc. (NASDAQ:HOLX) have earned an average recommendation of “Hold” from the sixteen ratings firms that are presently covering the stock, Marketbeat.com reports. Thirteen investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $79.3077.

Several research firms have recently weighed in on HOLX. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Leerink Partners upped their target price on Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a report on Tuesday, October 21st. Evercore ISI cut Hologic from an “outperform” rating to an “in-line” rating and dropped their price target for the stock from $79.00 to $78.00 in a research note on Monday, January 5th. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a report on Wednesday. Finally, Mizuho cut shares of Hologic from an “outperform” rating to a “neutral” rating and raised their target price for the stock from $70.00 to $78.00 in a report on Thursday, October 23rd.

Institutional Trading of Hologic

Several large investors have recently added to or reduced their stakes in the company. NewEdge Wealth LLC boosted its position in shares of Hologic by 3.8% in the third quarter. NewEdge Wealth LLC now owns 3,779 shares of the medical equipment provider’s stock worth $281,000 after buying an additional 138 shares during the period. Tokio Marine Asset Management Co. Ltd. lifted its stake in Hologic by 1.9% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 7,675 shares of the medical equipment provider’s stock worth $572,000 after acquiring an additional 142 shares in the last quarter. Capital Investment Counsel Inc boosted its position in Hologic by 2.6% during the 2nd quarter. Capital Investment Counsel Inc now owns 5,814 shares of the medical equipment provider’s stock worth $379,000 after acquiring an additional 150 shares during the period. BCS Private Wealth Management Inc. grew its stake in Hologic by 2.5% during the 4th quarter. BCS Private Wealth Management Inc. now owns 6,105 shares of the medical equipment provider’s stock valued at $455,000 after acquiring an additional 150 shares in the last quarter. Finally, Savant Capital LLC increased its holdings in shares of Hologic by 0.9% in the 3rd quarter. Savant Capital LLC now owns 19,776 shares of the medical equipment provider’s stock valued at $1,335,000 after purchasing an additional 170 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Performance

NASDAQ:HOLX opened at $74.93 on Monday. The company has a 50-day moving average of $74.89 and a 200-day moving average of $70.85. The firm has a market cap of $16.73 billion, a price-to-earnings ratio of 31.22, a price-to-earnings-growth ratio of 2.13 and a beta of 0.69. The company has a current ratio of 3.75, a quick ratio of 3.06 and a debt-to-equity ratio of 0.50. Hologic has a twelve month low of $51.90 and a twelve month high of $75.36.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing the consensus estimate of $1.09 by ($0.05). The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 20.00%. The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.87 earnings per share. Analysts forecast that Hologic will post 4.28 earnings per share for the current fiscal year.

Key Stories Impacting Hologic

Here are the key news stories impacting Hologic this week:

• Positive Sentiment: GYN Surgical business showed solid growth, providing a bright spot that can support longer-term revenue expansion if trends continue. HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash
• Positive Sentiment: Top-line growth was positive year-over-year (roughly +2.5%), showing continued demand across parts of the portfolio despite the quarter’s misses. Hologic Press Release (Q1 FY2026)
• Neutral Sentiment: Company filed an official Q1 release and provided detailed metrics (net margin ~13.8%, ROE ~20.1%) that investors will parse for guidance and margin recovery timelines. Hologic Announces Financial Results for First Quarter of Fiscal 2026
• Neutral Sentiment: Analyst notes and outlook pieces are weighing near-term headwinds vs. portfolio strength; future quarters and any updated guidance will likely be the main driver of sentiment. Examining the Future: Hologic’s Earnings Outlook
• Negative Sentiment: Q1 EPS and revenue missed consensus estimates, a primary reason for the stock reaction as investors reset near-term expectations. Hologic (HOLX) Misses Q1 Earnings and Revenue Estimates
• Negative Sentiment: Gross margin contracted roughly 150 basis points driven by Diagnostics weakness, suggesting margin recovery could take multiple quarters and pressuring near-term profitability. HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash
• Negative Sentiment: Market reactions and coverage noted shares edging lower after the print, reflecting investor concern until clearer signs of margin stabilization or guidance improvement emerge. Hologic misses Q1 earnings and revenue estimates, shares edge lower

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.